Literature DB >> 18084092

Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors.

Shihua Xu1, Brian M McKeever, Douglas Wisniewski, Douglas K Miller, Robert H Spencer, Lin Chu, Feroze Ujjainwalla, Ting Ting Yamin, Jilly F Evans, Joseph W Becker, Andrew D Ferguson.   

Abstract

The nuclear membrane protein 5-lipoxygenase-activating protein (FLAP) plays an essential role in leukotriene synthesis. Recombinant full-length human FLAP with a C-terminal hexahistidine tag has been expressed and purified from the cytoplasmic membrane of Escherichia coli. Diffraction-quality crystals of FLAP in complex with leukotriene-synthesis inhibitor MK-591 and with an iodinated analogue of MK-591 have been grown using the sitting-drop vapor-diffusion method. The crystals exhibit tetragonal symmetry (P42(1)2) and diffracted to a resolution limit of 4 A.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18084092      PMCID： PMC2344111          DOI： 10.1107/S1744309107055571

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN： 1744-3091


  21 in total

1.  Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

Authors:  S Charleson; P Prasit; S Léger; J W Gillard; P J Vickers; J A Mancini; P Charleson; J Guay; A W Ford-Hutchinson; J F Evans
Journal:  Mol Pharmacol       Date:  1992-05       Impact factor: 4.436

Review 2.  Prostaglandins and leukotrienes: advances in eicosanoid biology.

Authors:  C D Funk
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

3.  5-lipoxygenase-activating protein is an arachidonate binding protein.

Authors:  J A Mancini; M Abramovitz; M E Cox; E Wong; S Charleson; H Perrier; Z Wang; P Prasit; P J Vickers
Journal:  FEBS Lett       Date:  1993-03-08       Impact factor: 4.124

4.  A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.

Authors:  P Prasit; M Belley; M Blouin; C Brideau; C Chan; S Charleson; J F Evans; R Frenette; J Y Gauthier; J Guay
Journal:  J Lipid Mediat       Date:  1993 Mar-Apr

Review 5.  Discovery of inhibitors of the 5-lipoxygenase activating protein (flap).

Authors:  R N Young; J W Gillard; J H Hutchinson; S Léger; P Prasit
Journal:  J Lipid Mediat       Date:  1993 Mar-Apr

6.  Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors.

Authors:  P J Vickers; M Adam; S Charleson; M G Coppolino; J F Evans; J A Mancini
Journal:  Mol Pharmacol       Date:  1992-07       Impact factor: 4.436

7.  Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

Authors:  C Brideau; C Chan; S Charleson; D Denis; J F Evans; A W Ford-Hutchinson; R Fortin; J W Gillard; J Guay; D Guévremont
Journal:  Can J Physiol Pharmacol       Date:  1992-06       Impact factor: 2.273

8.  Identification and isolation of a membrane protein necessary for leukotriene production.

Authors:  D K Miller; J W Gillard; P J Vickers; S Sadowski; C Léveillé; J A Mancini; P Charleson; R A Dixon; A W Ford-Hutchinson; R Fortin
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

9.  Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.

Authors:  R A Dixon; R E Diehl; E Opas; E Rands; P J Vickers; J F Evans; J W Gillard; D K Miller
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

10.  Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.

Authors:  Andrew D Ferguson; Brian M McKeever; Shihua Xu; Douglas Wisniewski; Douglas K Miller; Ting-Ting Yamin; Robert H Spencer; Lin Chu; Feroze Ujjainwalla; Barry R Cunningham; Jilly F Evans; Joseph W Becker
Journal:  Science       Date:  2007-06-28       Impact factor: 47.728
View more
  4 in total

1.  Structures of the OmpF porin crystallized in the presence of foscholine-12.

Authors:  Georgia Kefala; Chihoon Ahn; Martin Krupa; Luis Esquivies; Innokentiy Maslennikov; Witek Kwiatkowski; Senyon Choe
Journal:  Protein Sci       Date:  2010-05       Impact factor: 6.725

Review 2.  Leukotrienes in atherosclerosis: new target insights and future therapy perspectives.

Authors:  Graziano Riccioni; Alessandra Zanasi; Nicola Vitulano; Barbara Mancini; Nicolantonio D'Orazio
Journal:  Mediators Inflamm       Date:  2010-01-26       Impact factor: 4.711

3.  Macrophage gene expression and foam cell formation are regulated by plasminogen.

Authors:  Riku Das; Swetha Ganapathy; Ganapati H Mahabeleshwar; Carla Drumm; Maria Febbraio; Mukesh K Jain; Edward F Plow
Journal:  Circulation       Date:  2013-02-11       Impact factor: 29.690

Review 4.  Two-Dimensional Crystallization Procedure, from Protein Expression to Sample Preparation.

Authors:  Qie Kuang; Pasi Purhonen; Hans Hebert
Journal:  Biomed Res Int       Date:  2015-08-27       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.